Axel H SchÃ¶nthal

List of Publications by Year
in descending order

144 papers	11,964 citations	44069 48 h-index	26613 107 g-index
147 all docs	147 docs citations	147 times ranked	21193 citing authors

#	Article	IF	Citations
1	Heterogeneous Responses and Isoform Compensation Dim the Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer. Molecular and Cellular Biology, 2022, 42, MCB0045921.	2.3	7
2	NEO100 enables brain delivery of bloodâ€'brain barrier impermeable therapeutics. Neuro-Oncology, 2021, 23, 63-75.	1.2	19
3	Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab005.	0.7	8
4	Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro-Oncology, 2021, 23, 1656-1667.	1.2	11
5	Heat shock protein-90alpha (Hsp90Î±) stabilizes hypoxia-inducible factor-1Î± (HIF-1Î±) in support of spermatogenesis and tumorigenesis. Cancer Gene Therapy, 2021, 28, 1058-1070.	4.6	17
6	Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers, 2021, 13, 3385.	3.7	2
7	The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics, 2021, 13, 2167.	4.5	12
8	Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats. Drug Testing and Analysis, 2020, 12, 268-279.	2.6	5
9	Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review. Biochemical Pharmacology, 2020, 181, 114149.	4.4	18
10	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS ONE, 2020, 15, e0238238.	2.5	7
11	Intravenous delivery of microRNA-133b along with Argonaute-2 enhances spinal cord recovery following cervical contusion in mice. Spine Journal, 2020, 20, 1138-1151.	1.3	10
12	Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models. Journal of Neurosurgery, 2020, 132, 959-967.	1.6	11
13	Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. Neuro-Oncology Advances, 2020, 2, vdaa160.	0.7	6
14	Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. , 2020, 11, 389.		4
15	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
16	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
17	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
18	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0

#	Article	IF	Citations
19	Cytotoxic impact of a perillyl alcoholâ€“temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989156.	3.2	7
20	The Rolipramâ€“Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway. Molecular Cancer Therapeutics, 2019, 18, 517-530.	4.1	7
21	Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. Oncology Letters, 2018, 15, 1263-1270.	1.8	38
22	NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. Molecular Cancer Therapeutics, 2018, 17, 625-637.	4.1	19
23	Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. Journal of Neurosurgery, 2018, 128, 695-700.	1.6	34
24	Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. International Journal of Molecular Sciences, 2018, 19, 3905.	4.1	57
25	Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. Cancers, 2018, 10, 362.	3.7	8
26	Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis. ACS Chemical Biology, 2018, 13, 3054-3058.	3.4	21
27	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4⁺T-lymphocyte counts. CNS Oncology, 2018, 7, CNS22.	3.0	49
28	Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram. International Journal of Molecular Sciences, 2018, 19, 277.	4.1	7
29	NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo. Oncotarget, 2018, 9, 37026-37041.	1.8	5
30	A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells. Cancer Letters, 2017, 400, 161-174.	7.2	11
31	Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 285-297.	2.3	24
32	Patient with Recurrent Glioblastoma Responding Favorably to Ketogenic Diet Combined with Intranasal Delivery of Perillyl Alcohol: A Case Report and Literature Review. Brazilian Neurosurgery, 2017, 36, 194-199.	0.1	3
33	Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. International Journal of Molecular Sciences, 2016, 17, 1463.	4.1	33
34	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
35	A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. Cancer Letters, 2016, 371, 240-250.	7.2	24
36	Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas. , 2016, 7, 1.		19

#	Article	IF	Citations
37	Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. Journal of Biomedical Science, 2015, 22, 71.	7.0	18
38	A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. Cancer Letters, 2015, 358, 144-151.	7.2	22
39	Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurgical Focus, 2015, 38, E12.	2.3	143
40	Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurgical Focus, 2015, 38, E8.	2.3	22
41	Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. Journal of Neurosurgery, 2015, 123, 362-372.	1.6	11
42	Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. American Journal of Cancer Research, 2015, 5, 1580-93.	1.4	37
43	NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas. Molecular Cancer Therapeutics, 2014, 13, 2004-2017.	4.1	52
44	Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurgical Focus, 2014, 37, E12.	2.3	136
45	A Novel Temozolomideâ€“Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo. Molecular Cancer Therapeutics, 2014, 13, 1181-1193.	4.1	43
46	Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochemical Pharmacology, 2013, 85, 653-666.	4.4	160
47	Repositioning of Verrucosidin, a Purported Inhibitor of Chaperone Protein GRP78, as an Inhibitor of Mitochondrial Electron Transport Chain Complex I. PLoS ONE, 2013, 8, e65695.	2.5	26
48	Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy. Scientifica, 2012, 2012, 1-26.	1.7	276
49	Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas. Molecular Cancer Therapeutics, 2012, 11, 2462-2472.	4.1	75
50	Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Letters, 2012, 325, 63-71.	7.2	54
51	Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Letters, 2012, 326, 143-154.	7.2	98
52	Targeting endoplasmic reticulum stress for cancer therapy. Frontiers in Bioscience - Scholar, 2012, S4, 412.	2.1	50
53	Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. International Journal of Cancer, 2012, 130, 2495-2504.	5.1	16
54	Targeting endoplasmic reticulum stress for cancer therapy. Frontiers in Bioscience - Scholar, 2012, S4, 412-431.	2.1	62

#	Article	IF	Citations
55	Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Letters, 2011, 302, 100-108.	7.2	91
56	Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. Cancer Letters, 2011, 304, 33-40.	7.2	23
57	Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Letters, 2011, 312, 245-252.	7.2	41
58	Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. Biochemical Pharmacology, 2011, 82, 600-609.	4.4	12
59	Adverse effects of concentrated green tea extracts. Molecular Nutrition and Food Research, 2011, 55, 874-885.	3.3	74
60	Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response. Current Pharmaceutical Design, 2011, 17, 2428-2438.	1.9	21
61	Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Journal of Neurosurgery, 2011, 114, 689-694.	1.6	18
62	Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma. , 2011, , 291-298.		0
63	Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leukemia Research, 2010, 34, 250-253.	0.8	21
64	Antiangiogenic Activities of 2,5-Dimethyl-Celecoxib on the Tumor Vasculature. Molecular Cancer Therapeutics, 2010, 9, 631-641.	4.1	21
65	Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 450-461.	1.7	19
66	Glioma-associated endothelial cells are chemoresistant to temozolomide. Journal of Neuro-Oncology, 2009, 95, 13-22.	2.9	44
67	Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Letters, 2009, 275, 163-169.	7.2	100
68	Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Letters, 2009, 282, 87-97.	7.2	49
69	Green tea polyphenols block the anticancer effects of bortezomib and other boronic acidâ€“based proteasome inhibitors. Blood, 2009, 113, 5927-5937.	1.4	265
70	Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy. , 2009, , 1037-1056.		0
71	Celecoxib transiently inhibits cellular protein synthesis. Biochemical Pharmacology, 2008, 75, 395-404.	4.4	29
72	COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Molecular Cancer, 2008, 7, 38.	19.2	61

#	Article	IF	Citations
73	Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells. American Journal of Pathology, 2008, 173, 575-585.	3.8	84
74	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opinion on Investigational Drugs, 2008, 17, 197-208.	4.1	78
75	Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib. Cancer Research, 2008, 68, 843-851.	0.9	131
76	Stress Chaperone GRP78/BiP Confers Chemoresistance to Tumor-Associated Endothelial Cells. Molecular Cancer Research, 2008, 6, 1268-1275.	3.4	146
77	Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. Journal of Neurosurgery, 2007, 106, 455-462.	1.6	102
78	Induction of Apoptosis by Celecoxib in Cell Culture: An Uncertain Role for Cyclooxygenase-2: Figure 1.. Cancer Research, 2007, 67, 5575-5576.	0.9	9
79	HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress. Cancer Research, 2007, 67, 10920-10928.	0.9	136
80	CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Nonâ€“Small-Cell Lung Cancer Cells. Molecular Pharmacology, 2007, 72, 1269-1279.	2.3	45
81	Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics, 2007, 6, 1262-1275.	4.1	120
82	The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas. Cancer Research, 2007, 67, 9809-9816.	0.9	392
83	Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. British Journal of Cancer, 2007, 97, 1465-1468.	6.4	96
84	Glioma-associated endothelial cells show evidence of replicative senescence. Experimental Cell Research, 2007, 313, 1192-1202.	2.6	26
85	Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. Journal of Biomedical Science, 2007, 14, 647-662.	7.0	15
86	Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Molecular Cancer, 2006, 5, 19.	19.2	80
87	Potential Misidentification of Cyclooxygenase-2 by Western Blot Analysis and Prevention Through the Inclusion of Appropriate Controls. Molecular Biotechnology, 2006, 34, 329-336.	2.4	19
88	The intracellular genistein metabolite 5,7,3â€²,4â€²-tetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway. Free Radical Biology and Medicine, 2006, 41, 1225-1239.	2.9	31
89	EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. International Journal of Cancer, 2006, 119, 1236-1248.	5.1	69
90	Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurgical Focus, 2006, 21, 1-8.	2.3	15

#	Article	IF	Citations
91	Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurgical Focus, 2006, 20, E20.	2.3	34
92	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. Cancer Research, 2006, 66, 11115-11119.	0.9	69
93	Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurgical Focus, 2006, 20, E21.	2.3	59
94	Potent Mimicry of Fibronectin-induced Intracellular Signaling in Glioma Cells by the Homodimeric Snake Venom Disintegrin Contortrostatin. Neurosurgery, 2005, 57, 141-153.	1.1	15
95	Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkittâ€™s lymphoma in vitro and in vivo. Cancer Biology and Therapy, 2005, 4, 571-582.	3.4	78
96	Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a nonâ€“COX-2 inhibitory analog of celecoxib. Blood, 2005, 106, 4330-4338.	1.4	56
97	Dimethyl celecoxib as a novel nonâ€“cyclooxygenase 2 therapy in the treatment of nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1406-1412.	0.8	26
98	The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. Journal of Neurosurgery, 2005, 103, 526-537.	1.6	12
99	Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53. Cancer Res 2003;63:5239â€“42.. Cancer Research, 2004, 64, 2937-2938.	0.9	1
100	Differential Effects of Selective COX-2 Inhibitors on Cell Cycle Regulation and Proliferation of Glioblastoma Cell Lines. Cancer Biology and Therapy, 2004, 3, 55-62.	3.4	77
101	Inhibition of tumor cell growth by triton X-100 through specific effects on cell-cycle-regulatory components. Journal of Biomedical Science, 2004, 11, 95-103.	7.0	2
102	Measuring Cyclin-Dependent Kinase Activity. , 2004, 281, 105-124.		7
103	Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone. Molecular Carcinogenesis, 2003, 38, 160-169.	2.7	7
104	Increased Expression of TATA-Binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis. Molecular and Cellular Biology, 2003, 23, 3043-3051.	2.3	62
105	Effect of Reproductive Hormones on Ovarian Epithelial Tumors: I. Effect. Cancer Biology and Therapy, 2002, 1, 300-306.	3.4	35
106	The Type IV Phosphodiesterase Inhibitor Rolipram Induces Expression Inhibitors p21Cip1 and p27Kip1, Resulting in Growth Inhibition, Increased Differentiation, and Subsequent Apoptosis of Malignant A-172 Glioma Cells. Cancer Biology and Therapy, 2002, 1, 268-276.	3.4	67
107	Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. BMC Molecular Biology, 2002, 3, 11.	3.0	4
108	Role of serine/threonine protein phosphatase 2A in cancer. Cancer Letters, 2001, 170, 1-13.	7.2	168

#	Article	IF	Citations
109	Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene, 2001, 20, 2134-2143.	5.9	98
110	Peroxisome Proliferator-activated Receptor Î³ Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase CÎ´ Pathway in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2001, 276, 47650-47657.	3.4	67
111	p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53. Journal of Biological Chemistry, 2001, 276, 1998-2006.	3.4	90
112	Induction of protein phosphatase type 2A in response to disruption of cell-matrix interactions. Journal of Cellular Physiology, 2000, 182, 88-96.	4.1	8
113	Changes in cytoskeletal organization in polyoma middle T antigen-transformed fibroblasts: Involvement of protein phosphatase 2A andsrc tyrosine kinases. Cytoskeleton, 2000, 47, 253-268.	4.4	5
114	Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. Molecular and Cellular Biochemistry, 2000, 203, 59-71.	3.1	29
115	Redox Regulation of p21, Role of Reactive Oxygen and Nitrogen Species in Cell Cycle Progression. , 2000, , 311-336.		0
116	Proliferation of Lacrimal Gland Acinar Cells in Primary Culture. Stimulation by Extracellular Matrix, EGF, and DHT. Experimental Eye Research, 2000, 70, 639-649.	2.6	39
117	Inhibitory Phosphorylation of PP1Î± Catalytic Subunit during the G1/S Transition. Journal of Biological Chemistry, 1999, 274, 29470-29475.	3.4	80
118	Mechanisms of G2 Arrest in Response to Overexpression of p53. Molecular Biology of the Cell, 1999, 10, 3607-3622.	2.1	169
119	Reduction of Ha-ras-induced cellular transformation by elevated expression of protein phosphatase type 2A. , 1999, 24, 246-254.		17
120	Expression and Activity of Cell Cycle-Regulatory Proteins in Normal and Transformed Corneal Endothelial Cells. Experimental Eye Research, 1999, 68, 531-539.	2.6	16
121	Role of p53 in aziridinylbenzoquinone-induced p21waf1 expression. Oncogene, 1998, 17, 357-365.	5.9	8
122	Anticancer Quinones Induce pRb-Preventable G2/M Cell Cycle Arrest and Apoptosis. Free Radical Biology and Medicine, 1998, 24, 848-854.	2.9	40
123	Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines. Journal of Biological Chemistry, 1998, 273, 5939-5947.	3.4	122
124	Analyzing Gene Expression with the Use of Serine/Threonine Phosphatase Inhibitors. , 1998, 93, 35-40.		7
125	Autoregulation of Protein Phosphatase Type 2A Expression. Journal of Biological Chemistry, 1998, 273, 19019-19024.	3.4	129
126	Role of PP2A in intracellular signal transduction pathways. Frontiers in Bioscience - Landmark, 1998, 3, d1262-1273.	3.0	107

#	Article	IF	Citations
127	Activation of p53-p21 Pathway in Response to Disruption of Cell-Matrix Interactions. Journal of Biological Chemistry, 1997, 272, 29091-29098.	3.4	74
128	Endoplasmic reticulum stress-inducible protein GRP94 is associated with an Mg2+-dependent serine kinase activity modulated by Ca2+ and GRP78/BiP. , 1997, 170, 115-129.		21
129	Induction of p21 Mediated by Reactive Oxygen Species Formed during the Metabolism of Aziridinylbenzoquinones by HCT116 Cells. Journal of Biological Chemistry, 1996, 271, 31915-31921.	3.4	63
130	Positive Regulation of cdc2 Gene Activity by Protein Phosphatase Type 2A. Journal of Biological Chemistry, 1996, 271, 5988-5992.	3.4	19
131	Activation of the C-fos promoter by increased internal pH. Journal of Cellular Biochemistry, 1995, 57, 630-640.	2.6	7
132	Regulation of gene expression by serine/threonine protein phosphatases. Seminars in Cancer Biology, 1995, 6, 239-248.	9.6	37
133	Gene amplification and multidrug resistance induced by the phosphatase-inhibitory tumor promoter, okadaic acid. Carcinogenesis, 1995, 16, 637-641.	2.8	17
134	Expression of c-Jun Proto-oncogene in Corneal Endothelium. Experimental Eye Research, 1994, 59, 335-341.	2.6	5
135	Positive and Negative Regulation of Cell Cycle Progression by Serine/Threonine Protein Phosphatases. , 1994, , 33-40.		2
136	Gene Regulation by Ca2+ATPases.. Annals of the New York Academy of Sciences, 1992, 671, 509-511.	3.8	3
137	Measuring animal well-being. Nature, 1992, 356, 556-556.	27.8	1
138	Regulation of Proto-Oncogene Expression and Rate of Protein Synthesis by the Tumor Promoter Okadaic Acid. , 1991, , 337-341.		0
139	Nuclear protooncogene products: fine-tuned components of signal transduction pathways. Cellular Signalling, 1990, 2, 215-225.	3.6	26
140	The Role of FOS in Gene Regulation. , 1990, , 77-91.		1
141	An Update of the Mammalian UV Response: Gene Regulation and Induction of a Protective Function. , 1989, , 149-165.		22
142	Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell, 1988, 54, 325-334.	28.9	637
143	Posttranscriptional regulation of c-fos mRNA expression. Nucleic Acids Research, 1987, 15, 1643-1659.	14.5	224
144	A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Frontiers in Oncology, 0, 12, .	2.8	3